Background {#Sec1}
==========

By 2050, older adults aged ≥60 years are expected to account for 34% of the population in Europe \[[@CR1]\]. While alcohol consumption changes over the life-course, with a decline in consumption in older age, recent evidence from nine UK based prospective cohort studies, have shown that drinking occasions tend to become more frequent among older adults \[[@CR2]\]. There is also evidence of a cohort effect, with successive birth cohorts reporting an increase in alcohol consumption across all age-groups, including among older adults \[[@CR3]\].

Even at relatively low levels of alcohol consumption, older adults can be vulnerable to harm, with physiological changes exacerbating these harms \[[@CR4], [@CR5]\]. Furthermore, older adults experience a disproportionate burden of alcohol related-harm; in England between 2009 and 2010, adults aged ≥65 years accounted for approximately 44% (461,400) of alcohol-related hospital admissions yet comprised of only 17% of the population \[[@CR6], [@CR7]\]. Alcohol-related deaths were also highest among those aged 55 to 74 years \[[@CR4]\].

Furthermore, the use of multiple medicines is increasing in older adults \[[@CR8]--[@CR11]\]. A recent Irish study reported an increase in polypharmacy from 17.8 to 60.4% between the years 1997--2012 in older adults aged ≥65 years \[[@CR11]\]. Certain medications have the potential to interact with alcohol; these medications are referred to as alcohol interactive (AI) medications \[[@CR12]\]. They may interact with alcohol by altering the metabolism (pharmacokinetic) or effects (pharmacodynamic) of alcohol and/or the medication \[[@CR12]\]. Certain interactions may occur with any alcohol consumption, whereas other interactions may follow a dose response, with the risk or severity of an interaction increasing with increasing levels of alcohol \[[@CR13]\]. AI medications, when combined with alcohol, increase the risk of medical complications such as hypoglycaemia, hypotension, sedation, gastrointestinal bleeds and liver damage, in older adults \[[@CR5], [@CR12]\]. For example, older adults are vulnerable to the sedating effects of alcohol and when combined with central nervous system (CNS) agents, such as psychotropic medications, older adults have an increased risk of sedation and drowsiness \[[@CR5]\]. Psychotropic medicines include antidepressants, sedatives/hypnotics, stimulants and neuroleptics, all of which act on the CNS and are commonly prescribed to older adults \[[@CR14]\]. Similarly, concurrent use of alcohol with cardiovascular agents, such as vasodilatory agents, increases the risk of hypotension in older adults \[[@CR5]\], with concurrent use with non-steroidal anti-inflammatory drugs (NSAIDs) increasing the risk of gastrointestinal bleeds \[[@CR12]\].

While a recent systematic review has assessed the prevalence of concurrent alcohol use and prescription sedative-hypnotic medicines in middle-aged and older adults, \[[@CR15]\] there have been no systematic reviews on the prevalence of concurrent use of alcohol and alcohol interactive medications beyond psychotropic medications and associated adverse outcomes in older adults. An older review did investigate the potential risk of combining alcohol with medications in older adults however the focus of the review was on the pharmacology and mechanism of action involved in alcohol-medication interactions and potential clinical implications of these interactions \[[@CR5]\]. Therefore this study aims to systematically review the prevalence of concurrent use of alcohol and alcohol interactive medications in older adults and associated adverse outcomes.

Methods {#Sec2}
=======

This systematic review was performed according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines \[[@CR16]\].

Search strategy {#Sec3}
---------------

A comprehensive systematic search was performed using MEDLINE (PubMed), Embase, Scopus and Web of Science. A combination of the following keywords and MeSH terms were used: "ethanol", "alcohol", "drug interactions", "drug alcohol interaction" and "aged". This search was supplemented by a search in Google Scholar and by hand searching references of retrieved articles. The search was restricted to English language articles and articles published since January 1990 to June 2016.

Study selection and data extraction {#Sec4}
-----------------------------------

Studies were included if they met the following eligibility criteria: Observational studies reporting on the concurrent use of alcohol and alcohol interactive (AI) medicines in the same or overlapping recall periods in older adults. Studies also had to report on the quantity or frequency of alcohol consumption. We excluded studies which exclusively sampled patients with specific illnesses, or those seeking treatment for alcohol use disorders (AUD) or illicit drug use.

Title and abstracts of identified studies were reviewed by one reviewer (AH) to determine potential eligibility. Full text articles were then reviewed by two reviewers (AH/GC) for those studies considered eligible from title/abstract, or when it was unclear whether a study met the inclusion criteria. The following data were extracted by two reviewers (AH/GC): year of publication, country, study sample, study design, measurement and definition of alcohol interactive (AI) medications, measurement of alcohol consumption, prevalence of alcohol use and AI medication use and prevalence of concurrent alcohol and AI medication use. Adverse outcomes associated with concurrent use of alcohol and AI medications were also extracted if reported. Any uncertainty in relation to study eligibility and data extraction was resolved through discussion between two reviewers (GC/AH).

Critical appraisal {#Sec5}
------------------

The risk of bias was evaluated, by two reviewers (AH/GC), using an adapted form of the Newcastle Ottawa cohort scale (NOS) \[[@CR17]\]. This amended NOS scale allowed for the evaluation of cross-sectional studies, focussing on the risk of selection bias and information bias, specifically misclassification bias of both exposures (alcohol and AI medications) and the outcome (concurrent use of alcohol and AI medications) across included studies.

Results {#Sec6}
=======

Of the 546 citations identified from this search strategy, 108 full text articles were assessed for eligibility, with 20 studies meeting the inclusion criteria \[[@CR14], [@CR18]--[@CR36]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of studies included in this review

Study characteristics {#Sec7}
---------------------

Ten of the included studies were conducted in Europe \[[@CR14], [@CR19], [@CR21]--[@CR23], [@CR25], [@CR27]--[@CR29], [@CR36]\], eight in North America \[[@CR18], [@CR20], [@CR24], [@CR30]--[@CR32], [@CR34], [@CR35]\] and two in Australia \[[@CR26], [@CR33]\]. (Table [1](#Tab1){ref-type="table"}) All studies were cross-sectional \[[@CR14], [@CR18]--[@CR36]\]. Study settings varied across studies with; community-dwelling \[[@CR14], [@CR19], [@CR21]--[@CR27], [@CR31], [@CR34]--[@CR36]\], both community dwelling or living independently in care facilities \[[@CR32]\], general populations \[[@CR20], [@CR28], [@CR33]\], hospital setting \[[@CR29]\], retirement communities \[[@CR18]\] and participants signed up to a pharmaceutical assistance contract for the elderly \[[@CR30]\] reported.Table 1Characteristics of included studiesReferenceSettingParticipants: N, sex, mean age (±sd), rangeStudy design (survey mode)Measurement &Definition:AI Medication(s)Alcohol Consumption Quantity/Frequency; thresholds appliedAdams 1995 \[[@CR18]\]United States (US), retirement community residents*N* = 311\
23% men\
83 (± 6 years)\
NRCross sectional (Mailed self-reported survey)Regular or occasional use of "high risk" meds in last 6 months: NSAIDS, aspirin, sedatives, narcotics, antidepressants, anti-hypertensives, antacids, H~2~ blockers, warfarin & meds for congestive heart failure, gout or diabetes. Reference source not reportedKhavari questionnaire: quantity -- frequency, last 6 months, None, 1--6 drinks/week or ≥7 drinks/week\
1 drink = 12 oz. of beer, 5 oz. of wine, 3 oz. of fortified wine or 1.5 oz. of hard liquor.Aira 2005 \[[@CR19]\]Finland, community dwelling older adults*N* = 521\
27% men\
81 (± 4.4 years)\
Range: 75--95.7 yearsCross sectional (Nurse interview; prescriptions & containers)Current use of medications having potential interactions with alcohol: Acetaminophen (Paracetamol), anticonvulsants, antidepressants, TCAs, antihistamines, benzodiazepines, H~2~ receptor antagonists, neuroleptics, nitrates, NSAIDs, opiates & warfarin. Reference source not reportedBeverage specific quantity-frequency, last 12 months: None, 1--7 units/week, \>7 units /week\
1unit = 11-12 g of alcoholBreslow 2015 \[[@CR20]\]US, general population\
≥ 20 years≥65 years *N* = 7183\
≥20 years *N* = 26,657\
51% men\
NRCross sectional (Interviews in-home, medication containers)Use of AI prescription medication, past month; identified using (i) [Drugs.com](http://drugs.com), (ii) [Caremark.com](http://caremark.com), (iii) [Healthline.com](http://healthline.com), (iv) DailyMed databases & (v) references from 3 publications \[[@CR12], [@CR43], [@CR44]\] including: cardiovascular agents, CNS agents, coagulation modifiers, GI, metabolic, psychotherapeutic & respiratory agentsQuantity -- frequency in last 12 months: None, for women of all ages & men \>65 years: moderate consumption: \>0--7 drinks/week & heavier drinkers (\> 7 drinks/week). For men 20--64 years moderate: \>0--14 drinks/week & heavier \>14drinks/weekCousins 2013 \[[@CR21]\]Ireland, community dwelling older adults ≥60 years*N* = 3815\
46.6% males\
69.7 (±7.3 years)\
Range: 60--99 yearsCross sectional (Nurse led interviews in-home; medications reviewed & self-completed questionnaire)Current or regular use of medications with potential to interact with alcohol identified using Stockley's Drug Interactions, British National Formulary and Irish Medicines Formulary: cardiovascular agents, CNS agents, antihistamines, blood agents, antidiabetic agents, anti-infectives, GI drugs, immunomodulators & muscle relaxantsQuantity-frequency, past 6 months: None,\
Light/moderate (≤ 4 drinks/day or 10 drinks/ week) and heavy drinkers (\>4 drinks/day or 10 drinks/ week)\
1 drink = 10 g of alcoholDel Rio 1996 \[[@CR23]\]Spain, community dwelling adults\
≥ 16 years≥66 years *N* = 3003\
≥ 16 years *N* = 21,084\
48% men\
NRCross sectional (survey with interview)Medication use, past 2 weeks. No reference source reportedBeverage specific quantity-frequency, past 2 weeksDel Rio 2002 \[[@CR22]\]Spain, community dwelling adults\
≥ 16 years≥66 years = 1025\
≥16 years *N* = 6396\
48% men\
NRCross sectional (survey with interview)Benzodiazepine use, past 2 weeksBeverage specific quantity-frequency past 2 weeks: Low (men: ≤ 21 units/week, women: ≤ 14 units/week), moderate (men: 22--50 units/week, women: 15--35 units/week) & high consumption (men: \>50 units/week & women: \>35 units/week)\
1 unit = 10 g of alcoholDu 2008 \[[@CR14]\]Germany, community dwelling older adults*N* = 1605\
45.2% men\
NR\
Range: 60--79 yearsCross sectional (survey & interview; prescriptions or original containers)Any psychotropic medication use in past 7 days: ATC nervous system drugs coded N00. (Excluded drugs coded N02B aspirin & paracetamol, except for N02BA71) Opiate codeines used as antitussives were merged with N02A & opiates for GI conditions (A07D) were not recordedBeverage specific quantity-frequency, past 12 months: Problem use (risky drinking): daily consumption ≥10 g for women & ≥ 20 g for menForster 1993 \[[@CR24]\]US, community dwelling older adults*N*=667\
39.9% men\
74.1 (±6.6 years)\
NRCross sectional (survey & interview; medication containers)Prescription or OTC medications currently or past month: AI drugs defined by study clinical team: OTC painkillers, anti-hypertensives, diuretics, OTC cold preparations, arthritis medications, heart medications, antibiotics, mind altering medications, chest pain medications, pain medications, diabetes medications, ulcer medications, sleeping pills, OTC nasal sprays, steroids, blood agents, insulin, seizure medications & OTC asthma medicationFrequency: never, rarely, sometimes & regularlyIlomaki 2008 \[[@CR25]\]Finland, community dwelling older adults*N*=1,774\
48.1% men\
63 years (NR)\
Range: 53-73 yearsCross sectional (mailed survey & interview; prescriptions brought if any problems)Regular use of psychotropic drugs at time of interview: antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants & combinationsBeverage specific quantity-frequency past 12 months: frequent ≥2 times/week, binge (men ≥5 units/occasion: women ≥4 units/occasion) & heavy drinking (men: \>14 units/week: women \>7 units/week\
1 unit=12 g of alcoholIlomaki 2013 \[[@CR26]\]Australia, community dwelling older men≥70 years N=1,705\
100% men\
NR\
NRCross sectional (Interview: medications brought)Antidepressants (including SSRIS, TCAs, MAOIs and others) & SADs (including benzodiazepines and benzodiazepine-like hypnotics)Beverage specific quantity-frequency past 12 months: daily (7days/week), binge (≥5 drinks at least once/month), heavy (\>2 drinks/day) & problem drinkers (CAGE score ≥2). Nondrinkers: former or never drinkers\
1 drink=10 g of alcoholImmonen 2012 \[[@CR27]\]Finland, community dwelling older adults≥ 65 years N=1,395\
35.5% men\
78.7 years (NR)\
NRCross sectional (mailed survey)Current prescribed medications: Swedish, Finnish Interaction X-referencing (SFINX) interaction database identified significant drug-alcohol interactions: metronidazole, tinidazole, disulfiram, griseofulvin, prazosin, metformin & tacrolimus. CNS agents, hypoglycaemics and warfarinBeverage specific quantity-frequency: At risk\
(\>7 drinks/ week, or ≥5 drinks on a typical drinking day or ≥3 drinks several times/week), moderate drinkers (at least 1 drink/month but \< 7 drinks/week) & minimal/non-users (\<1 drink/month)\
1 drink = 12 g of alcoholJohn 2007 \[[@CR28]\]Germany, general population\
≥ 20 yearsNR\
≥20 years *N*= 4290\
49% men\
NR\
Range: 20-79 yearsCross sectional; (Interview; container or participant provided information on current medications)Use of sedative, hypnotics or anxiolytics (SHA) medicines including: barbiturates (& derivatives), benzodiazepines (& derivatives), carbamates, piperidinedione derivatives, hypnotics or anxiolytics & combinations of sedatives and hypnotics. SO group: included SHA and opioid, past 7 daysQuantity of beverage specific alcohol consumed on last working day and last weekend: Risk drinking (men: \>30 g/day & women \>20g/day)Lagnaoui 2001 \[[@CR36]\]France, community dwelling older adults≥65 years *N*=3767\
41.7% men\
NR\
NRCross sectional; (Interview at home; adhoc questionnaire; visual inspection)Benzodiazepine useQuantity: Daily wine consumption divided into: I) none ii) moderate up to 0.25 l day ^-1^ & iii) heavy \> 0.25 l day ^-1^ ( l day^−1^= litres consumed daily)Onder 2002 \[[@CR29]\]Italy, hospital admissions among older adults*N* = 22,778\
45% men\
70.3 (± 16 years)\
NRCross sectional (questionnaire at admissions)Medications taken prior to admission, during hospital stay & prescribed at discharge: drugs classified according to risk of causing adverse drug reactions using Naranjo algorithmQuantity of daily consumption prior to hospital\
admission: (daily wine units). Non-drinkers & moderate drinkers only, heavy alcohol users were excludedPringle 2005 \[[@CR30]\]US, Pennsylvania Pharmaceutical Assistance Contract for the Elderly prescription drug users*N* = 83,321\
19% men\
78.8 (± 6.9 years)\
Range: 65-106 yearsCross sectional (survey & prescription claims data)Filled prescriptions, past 45 days: drugs with potential for alcohol interactions (using First\
Databank Inc. Drugs) with one of the following warnings considered AI:\
1. May cause drowsiness; alcohol may intensify this effect\
2. Do not drink alcohol when taking this medication\
3. May cause drowsiness and dizziness; alcohol may intensify this effect\
4. Limit alcohol while taking this medication; daily use of alcohol may increase risk of stomach bleedsCurrent quantity-frequency:\
Light: 1-7 drinks/month\
Moderate: 8-30 drinks/month\
Heavy: \>30 drinks/monthQato 2015 \[[@CR31]\]US, community dwelling older adults*N*= 2975\
48.6% men\
NR\
Range: 57-85 yearsCross sectional (In house interviews & observation medication bottles)Current or regular use (daily or weekly) with potential to interact with alcohol (Thomson Micromedex database). Drugs categorised according to severity of interaction:\
1. Contraindicated: Drugs contraindicated for use with alcohol\
2. Major: may be life-threatening or require medical intervention to prevent serious adverse events\
3. Moderate: may result in exacerbation of individuals condition or require alternative therapy\
4. Minor: limited clinical effectsQuantity-frequency last 3 months:\
Non-regular drinkers: (none or \<1 drink/week)\
Light --regular: (≥ 1 drink/week & 1 drink/day)\
Heavy-regular: (≥ 1 drink/week & 2-3 drinks/day)\
Binge-regular: (≥ 1 drink/week & ≥4 drinks/day)Sheahan 1995 \[[@CR32]\]US, community dwelling & independent living congregate care facility older residents≥ 55 years *N*=1028\
26.9% men\
73.5 (± 9.47 years)\
NRCross sectional (In house interviews & medication container labels)Psychotropic medications in past year: sedatives/hypnotics, anxiolytics/tranquilizers, antidepressants & prescription pain medicationsFrequency, past year. Average number of times/week; month or year consumed alcohol.\
Number of drinking days in past year calculatedVeldhuizen 2009 \[[@CR34]\]Canada, community dwelling ≥ 15 yearsNR\
≥15 years: *N*=36,984\
49% men\
NCross sectional study (Survey with interview, medication containers)Use of benzodiazepines (N03AE, N05BA and N05CD), non-benzodiazepine hypnotics (zopiclone, eszopiclone, zolpidem and zaleplon) during past 2 days among those who reported use in past 12 monthsQuantity-frequency on each of the previous 7 days among those drinking in past year: No drinking, moderate & heavy drinking (\>14 drinks/week for men/ \>9 drinks/week for women) or binge drinking (\>4 drinks/day for women or 5 drinks/day for men)\
1 drink= 1 bottle or can of beer/ glass of draft, 1 glass of wine/cooler or 1 ½ oz of liquorWong 2016 \[[@CR35]\]America, community dwelling older adults*N*=2444\
33% men\
76.84 (±8.13 years)\
Range: 60-103 yearsCross sectional (Face to face interviews)Prescriptions and OTC medications taken daily. Number of medications: low ≤ 1, moderate 2-4 & high ≥5Quantity-frequency\
Abstainers: no to alcohol & 0 drinkers/month, Light: yes to alcohol & \<29 drinks/month, Moderate: yes to alcohol & 30 drinks/month, Heavy: yes to alcohol & \>31 drinks/month\
1 drink= 14g of alcohol

Sample sizes varied from 311 to 83,321 participants \[[@CR18], [@CR30]\] . Men and women were included in all studies, with the exception of one Australian study which only included men \[[@CR26]\]. Nine studies reported on a wide range of prescription and/or over the counter (OTC) medicines with potential to interact with alcohol \[[@CR18]--[@CR21], [@CR24], [@CR27], [@CR29]--[@CR31]\] . Three studies investigated any medication use during the recall period \[[@CR23], [@CR33], [@CR35]\], and a further eight focused on psychotropic medications \[[@CR14], [@CR22], [@CR25], [@CR26], [@CR28], [@CR32], [@CR34], [@CR36]\]. Of the eight studies focusing on psychotropic medications, five investigated psychotropic medications alone \[[@CR22], [@CR25], [@CR26], [@CR34], [@CR36]\] and three studies also included analgesics \[[@CR14], [@CR28], [@CR32]\].

Of the nine studies focusing on a wide range of AI medications, all studies classified central nervous system (CNS) agents as AI medications (Table [1](#Tab1){ref-type="table"}). Consistent with those studies investigating psychotropic medications \[[@CR14], [@CR22], [@CR25], [@CR26], [@CR28], [@CR32], [@CR34], [@CR36]\], the following drug classes were classified as AI medications, sedatives/hypnotics \[[@CR18]--[@CR21], [@CR24], [@CR27], [@CR30], [@CR31]\], antidepressants \[[@CR18]--[@CR21], [@CR27], [@CR30], [@CR31]\], opioids/narcotics \[[@CR18]--[@CR21], [@CR27], [@CR30], [@CR31]\], anticonvulsants \[[@CR19]--[@CR21], [@CR24], [@CR27], [@CR30], [@CR31]\] and anti-psychotics \[[@CR19]--[@CR21], [@CR27], [@CR29], [@CR30]\]. After CNS agents, cardiovascular medicines (CVS) were the most common AI medicines \[[@CR18]--[@CR21], [@CR24], [@CR27], [@CR29]--[@CR31]\], followed by antidiabetic drugs \[[@CR18], [@CR20], [@CR21], [@CR24], [@CR27], [@CR29]--[@CR31]\], warfarin \[[@CR18]--[@CR21], [@CR24], [@CR27], [@CR30], [@CR31]\], gastrointestinal agents \[[@CR18]--[@CR21], [@CR24], [@CR30], [@CR31]\], non-steroidal anti-inflammatory drugs (NSAIDs) \[[@CR18]--[@CR21], [@CR29]--[@CR31]\], antibiotics/anti-infectives \[[@CR21], [@CR24], [@CR27], [@CR29]--[@CR31]\] and anti-histamines \[[@CR19]--[@CR21], [@CR30]\].

Quality assessment {#Sec8}
------------------

The methodological quality of the included studies is detailed in Table [2](#Tab2){ref-type="table"}. The external validity was high in 4 studies, as they reported on random population samples of community dwelling older adults aged ≥60 or ≥65 years \[[@CR21], [@CR24], [@CR27]\] or in the case of Breslow et al., a random population sample with oversampling of older adults aged ≥60 years \[[@CR20]\]. Ten studies were considered to have moderate external validity; five studies sampled random community dwelling older adults but with age restrictions which may have introduced selection bias \[[@CR14], [@CR19], [@CR25], [@CR26], [@CR31]\] such as including adults aged between 53 and 75 years \[[@CR25]\] or only including adults ≥75 years \[[@CR19]\]. A further five studies reported on random population samples of community dwelling adults with subgroup analysis of older adults, however they did not report oversampling of older adults \[[@CR22], [@CR23], [@CR28], [@CR33], [@CR34]\]. The six remaining studies were considered to have poor external validity, as the risk of selection bias is considered to be high \[[@CR18], [@CR29], [@CR30], [@CR32], [@CR35], [@CR36]\]. For example, Pringle et al. recruited enrollees in the Pennsylvania pharmaceutical assistance contract for the elderly, which may not be representative of all older adults as the members are older (mean age 78.8 years) and more likely to be female and white with multiple chronic conditions \[[@CR30]\].Table 2Results of the critical appraisal of included studiesStudyRepresentativeness of sampleAscertainment of alcohol consumptionAscertainment of AI medications (classified)Ascertainment of AI medications (measured)Assessment of the outcome (concurrent use)Study total:a) Cross Sectional Studies Outcome of Interest Concurrent use of alcohol and medications:Adams et al. 1995 \[[@CR18]\]++++++Aira et al. 2005 \[[@CR19]\]++++++++++Breslow et al. 2015 \[[@CR20]\]++++++++++++++++++++Cousins et al. 2014 \[[@CR21]\]++++++++++++++++++++Del Rio et al. 1996 \[[@CR23]\]++++++Del Rio et al. 2002 \[[@CR22]\]++++++++++Du et al. 2008 \[[@CR14]\]++++++++++++++++++Forster et al. 1995 \[[@CR24]\]++++++++++Ilomaki et al. 2008 \[[@CR25]\]++++++++++++++++++Ilomaki et al. 2013 \[[@CR26]\]++++++++++++++++++Immonen et al. 2012 \[[@CR27]\]++++++++++John et al. 2007 \[[@CR28]\]++++++++++++Lagnaoui et al. 2001 \[[@CR36]\]++++Onder et al. 2002 \[[@CR29]\]++Pringle et al. 2005 \[[@CR30]\]++++++++++Sheahan et al. 1995 \[[@CR32]\]++++++++++Qato et al. 2015 \[[@CR31]\]++++++++++++++++++Swift et al. 2007 \[[@CR33]\]++Veldhuizen et al. 2009 \[[@CR34]\]++++++++++++++++++Wong et al. 2016 \[[@CR35]\]

Internal validity was assessed by evaluating the potential risk of misclassification bias for both exposure and outcome across studies. Ten studies were considered to have a low risk of misclassifying exposure to medications which have the potential to interact with alcohol, as they used prescription claims data or in house inventories where they recorded details from the labels of medication containers or prescriptions and provided references supporting the inclusion of medicines as potentially alcohol interactive (Table [2](#Tab2){ref-type="table"}) \[[@CR14], [@CR20], [@CR21], [@CR25], [@CR26], [@CR28], [@CR30]--[@CR32], [@CR34]\]. The potential for misclassification bias was considered high in the remaining studies as they relied on self-report for medication exposure \[[@CR18], [@CR22], [@CR23], [@CR27], [@CR29], [@CR33], [@CR35], [@CR36]\] and/or did not provide references supporting the inclusion of medicines as potentially alcohol interactive \[[@CR19], [@CR23], [@CR24], [@CR29], [@CR33], [@CR35]\].

While all studies relied on self-reported alcohol consumption, thus introducing potential biases in recall and reporting, 11 studies were considered to have a lower risk of bias as they reported on both quantity and frequency of alcohol consumption within a specified recall period, ranging from 1 week to 12 months (Table [2](#Tab2){ref-type="table"}) \[[@CR14], [@CR18]--[@CR23], [@CR25], [@CR26], [@CR31], [@CR34]\]. The risk of misclassification bias, specifically underestimating exposure to alcohol, was considered to be higher in the remaining studies as they used quantity or frequency measures alone \[[@CR24], [@CR32], [@CR35]\], did not specify the recall period \[[@CR24], [@CR27], [@CR30], [@CR35]\], restricted measurements to wine consumption \[[@CR29], [@CR36]\] and used a very narrow recall period "last working day or last weekend" \[[@CR28]\]. Ascertainment of exposure to alcohol was unclear in one study \[[@CR33]\].

In relation to outcome assessment, no study directly measured the concurrent use of alcohol and AI medications, rather all studies inferred concurrent use. Although possible for all studies, the risk of misclassifying the outcome of concurrent use was considered lowest in those studies identified as having a low risk of misclassifying exposure, who used the same recall period for both exposures or inferred concurrent use based on alcohol consumption within a specific recall period, ranging between 1 week and 12 months, and current or regular medication use (Table [2](#Tab2){ref-type="table"}) \[[@CR14], [@CR20], [@CR21], [@CR25], [@CR26], [@CR31], [@CR34]\].

Summary of findings {#Sec9}
-------------------

As noted in Table [1](#Tab1){ref-type="table"}, all estimates relate to studies from North America, Europe and Australia.

Alcohol consumption {#Sec10}
-------------------

The prevalence of alcohol consumption ranged between 57 and 63% in studies reporting on nationally representative samples of community dwelling older adults (Table [3](#Tab3){ref-type="table"}) \[[@CR21], [@CR24], [@CR27]\]. Prevalence estimates of alcohol consumption were generally lower in studies sampling restricted age-groups, for example estimates ranged between 33.7 and 44% for studies restricted to older adults aged \>70 years \[[@CR26]\] and \>75 years \[[@CR19]\]. Similarly, prevalence estimates of alcohol consumption were generally lower in those studies considered to have a high risk of selection bias \[[@CR18], [@CR29], [@CR30], [@CR32], [@CR35]\]. For example, 20% of older adults registered on the Pennsylvania pharmaceutical assistance contract for the elderly reported alcohol consumption \[[@CR30]\]. All studies reporting on gender differences identified a higher prevalence of alcohol consumption in men \[[@CR19]--[@CR21], [@CR25], [@CR29], [@CR31], [@CR36]\].Table 3Summary of results; prevalence of alcohol consumption, alcohol interactive medication use and concurrent use among older adultsStudyPrevalence of alcohol consumption in older adults (gender);\
Heavy/Problem drinking (gender)Prevalence of alcohol interactive medication use:Concurrent use reported among:\
Total sample of older adultsConcurrent use reported among:\
AI medication usersConcurrent use reported among:\
Current drinkersStudies reporting on a wide range of alcohol interactive (AI) medicines (*n* = 13 studies)Adams 1995 \[[@CR18]\]47% drank alcohol in previous 6 months\
Heavy (\>7 drinks/week): 8%80% used one or more of the following in the last 6 months: NSAIDS, aspirin, sedatives, narcotics, antidepressants, anti-hypertensives, antacids, H~2~ blockers, warfarin & meds for congestive heart failure, gout or diabetes38% reported concurrent use of alcohol and AI medications, 6% reported concurrent heavy alcohol consumption and AI medicationsOverall drinkers: 80% used an AI medication (50% used anti-hypertensives, 27% used aspirin, 20% used NSAIDs, 18% used chronic heart failure drugs, 11% used sedatives; 5% used narcotics, 5% used warfarin, 4% used diabetic drugs, 3% used antidepressants, 3% used drugs for gout)\
Heavy drinkers: 80% used an AI medication (48% used anti-hypertensives, 28% used aspirin, 16% used NSAIDs, 16% used chronic heart failure drugs, 4% used sedatives, 4% used narcotics, 4% used warfarin, 8% used diabetic drugs, 12% used antidepressants, 4% used drugs for gout)Aira 2005 \[[@CR19]\]44% drank alcohol in previous 12 months (66% of men & 37% of women)\
Heavy (\>7 units/week): 7% of men & 0% of women90% used one or more of the following regularly or as needed: acetaminophen, anticonvulsants, antidepressants, antihistamines, benzodiazepines, histamine H2 receptor agonist, neuroleptics, nitrates, NSAIDs, opiates or warfarin39% reported concurrent use of alcohol and AI medications, 1.9% reported concurrent heavy alcohol consumption and AI medications. Concurrent alcohol and specific AI medications: 7.5% acetaminophen, 0.19% anticonvulsants, 5.16% antidepressants, 0.76% antihistamines, 11% benzodiazepines, 1.15% histamine H2 receptor agonist, 2.29% neuroleptics, 23% nitrates, 29% NSAIDs, 3.8% opiates & 3.6% warfarinOverall AI medication users: 44% drank alcohol (36% acetaminophen users, 17% anticonvulsants users, 40% antidepressants users, 21% antihistamines users, 38% benzodiazepine users, 43% histamine H2 receptor agonist users, 25% neuroleptic users, 43% nitrate users, 46% NSAID users, 38% opiate users & 40% warfarin users)Overall drinkers: 88% used AI medicationsBreslow 2015 \[[@CR20]\]47% drank alcohol in previous 12 months (55% of men & 39.7% of women)78.6% used one or more of the following: cardiovascular agents, CNS agents, coagulation modifiers, GI agents, metabolic agents, psychotherapeutic agents, respiratory agents35% reported concurrent use of alcohol and AI medications. Concurrent alcohol and specific AI medications: 28% cardiovascular agents, 10% CNS agents (1.8% anticonvulsants, 2% anxiolytic/sedative/hypnotic, 2% narcotics, 2.2% NSAIDs), 3% coagulation modifiers, 2.2% GI agents, 16.9% metabolic agents, 3.9% psychotherapeutic agents (3.8% antidepressants), 2.1% respiratory agentsOverall AI medication users: 45% drank alcohol (44% cardiovascular agents users, 40% CNS agent users (34% anticonvulsants, 40% anxiolytic/sedative/hypnotic, 43% NSAID), 44% coagulation modifier users, 43% GI agent users, 43% metabolic agent users, 41% psychotherapeutic agent users (42% antidepressants), 48% respiratory agent users)Overall drinkers: 77.8% took AI medications (61.3% used cardiovascular agents,\
22% used CNS agent (3.9% used anticonvulsants, 4.6% used anxiolytic/sedative/hypnotic, 4.8% used NSAID), 6% used coagulation modifier, 4.7% used G I agent users, 36.5% used metabolic agent, 9.6% used psychotherapeutic agent (9.2% used antidepressants), 4.6% used respiratory agent)Cousins 2013 \[[@CR21]\]62.8% drank alcohol previous 6 months (72% of men & 59% of women)\
Heavy (\>4 drinks/day or \>10 drinks/week): 20% (32% of men & 11% of women)\
CAGE: 8% (12.2% of men & 4% of women)72% took one or more of the following: cardiovascular agents, CNS agents, antihistamines, Blood, antidiabetic agents, anti-infectives, GI agents, immunomodulators or muscle relaxantsOverall AI medication users concurrent use of alcohol: 60% drank alcohol (60% cardiovascular agent users, 53.5% CNS agent users (59% of NSAID users, 54% hypnotic users, 44% anxiolytic users, 52.9% antidepressant users), 66.9% antihistamine users, 58.5% blood medication users, 54% antidiabetic agent users, 47% anti-infective users, 50% GI agent users, 51% immunomodulator users &80.3% muscle relaxant users)\
AI medication users concurrent heavy alcohol consumption: 25% antihistamine users, 20% cardiovascular agent users, 20% blood (anti-coagulant or anti-platelet) users, 20% anti-diabetic agent users, 16% CNS agent users (13% users of anti-epileptic agents; 13% antipsychotic agents; 13% hypnotic users & 18% antidepressant users)Del Rio 1996 \[[@CR23]\]Approximately 20% drank alcohol at least once per day in the past 2 weeks75--80% took one or more medication in previous 2 weeks18% reported concurrent use of alcohol and AI medicationsForster 1993 \[[@CR24]\]57.1% reported using alcohol\
16.9% admitted to drinking enough to become "lightheaded"Not Reported25% reported concurrent use of alcohol and AI medications. Concurrent alcohol and specific AI medications: 19% OTC analgesics, 6.9% antihypertensives, 5.4% diuretics; 4.3% OTC cold preparations, 2.1% mind altering drugs, 1.5% diabetes pills, 1.5% prescription pain medication, 1.2% sleeping pills, 0.6% prescription blood thinners, 0.6% insulin & 0.3% seizure medicationsImmonen 2013 \[[@CR27]\]62.6% drank alcohol\
At risk drinking (\>7 drinks/week, or ≥5 drinks on typical drinking day, or ≥3 drinks several times/week): 7.9%42% took one or more of the following: metronidazole, tinidazole, disulfiram, griseofulvin, prazosin, metformin & tacrolimus. CNS agents, hypoglycaemics and warfarinOverall AI medication users: 62.2% drank alcoholHeavy or at risk drinkers: 42.2%% took AI medications (2.2% used antipsychotics, 4.4% used anti-depressant, 6.7% used anxiolytics, 11.1% used hypnotics/sedatives, 5.6% used anti-epileptics, 3.3% used opioids, 11.1% used warfarin & 13.3% used metformin)Onder 2002 \[[@CR29]\]54.2% drank ≤40 g of wine/day prior to hospital admission (68.1% of men & 42.8% of women)27% used diuretics, 23% digoxin, 17.7% calcium channel blockers, 16% ACE inhibitors, 15% aspirin & anti-platelets, 9% oral hypoglycaemic agents, 6% NSAIDs, 6% antibiotics, 5.2% nitrates, 5% insulin, 4% steroids & 3.2% antipsychoticsOverall wine drinkers: 26% used diuretics, 3.8% oral hypoglycaemic agents, 2.6% antipsychotics & 1.8% insulinPringle 2005 \[[@CR30]\]20.3% drank alcohol\
Heavy (\> 30 drinks/month): 1.2%77.4% used on or more AI medicationOverall AI medication users concurrent use of alcohol: 19% drank alcohol (18.4% cardiovascular agent users, 18% CNS agent users (20% of NSAID users, 16.8% anxiolytic/hypnotic/sedative users& 16% antidepressant users), 20% antihistamine users, 14% blood medication users, 13% antidiabetic agent users, 16% anti-infective users, 14% GI agent users & 16% muscle relaxant users)Qato 2015 \[[@CR31]\]41% were regular drinkers in the past 3 months (59.3% of men & 40.7% of women)\
Heavy (2--3 drinks/day): 19.7%57.7% used at least one AI medication.21% reported concurrent use of alcohol and AI medicationsOverall drinkers (Regular drinkers): 51% used AI medications (8.4% used antidiabetic agents, 6.6% used analgesics, 2.4% used narcotics, 5.3% used acetaminophen, 26.7% used aspirin, 18.9% used psychotropic medication, 8.5% used antidepressants, 6% used anxiolytic/sedative/hypnotics & 4% used warfarin)Swift 2007 \[[@CR33]\]18% drank alcohol daily in past 12 months87.3% used at least one AI medication in last 24 h35.4% reported concurrent use of alcohol and AI medications in previous 24 hWong 2016 \[[@CR35]\]38% consumed alcohol\
Heavy (\> 31 drinks/month): 6%83% reported any medication use31% reported concurrent use of alcohol and medications& 1.4% reported concurrent heavy alcohol consumption and medication useStudies reporting on psychotropic medicines (*n* = 8 studies)Del Rio 2002 \[[@CR22]\]Not Reported13.4% used benzodiazepines in previous 2 weeksOverall benzodiazepine users concurrent use of alcohol: 23% (56--66 years), approx. 15% (66--75 years) & approx. 10% (\>75 years)Du 2008 \[[@CR14]\]47.3% drank alcohol at least once in the last-week\
Heavy drinking (≥10 g/day for women/ ≥ 20 g/day for men): 14.8%20% reported use of at least one psychotropic medication.7.4% reported concurrent use of alcohol and psychotropic medications & 2.4% reported concurrent heavy alcohol consumption and psychotropic medication useOverall psychotropic medication users concurrent use of alcohol: 37.5%Overall drinkers: 16% used psychotropic medicationIlomaki 2008 \[[@CR25]\]76.7% drank alcohol in previous year (87.5% of men & 68.9% of women)\
Heavy drinking (\>14 units/week men & \>7 units/week women): 12.6% (16.6% of men & 7.9% of women)11.5% reported use of at least one psychotropic medicationOverall psychotropic medication users concurrent use of alcohol: 38.9% of male users & 14.7% of female users were frequent drinkers, 25.9% of male users & 8.3% of female users were heavy drinkersIlomaki 2013 \[[@CR26]\]33.7% drank alcohol daily in the past 12 months\
Heavy drinking (\>2 drinks/day): 19.2%\
Problem drinkers (CAGE): 11%13.6% reported use of at least one psychotropic medication (8% reported antidepressant use, 5.7% sedative or anxiolytics use & 1.6% both drug classes)Overall antidepressant users: 27.1% consumed alcohol daily & 15% heavy drinkers\
Sedative or hypnotic users: 42.7% consumed alcohol daily & 26% heavy drinkersJohn 2007 \[[@CR28]\]Prevalence not reported\
Risky drinking (\>20 g/day women & \>30 g/day men): 15.1% of men & 3.2% of women (excludes users of sedative-hypnotic-anxiolytics and opioids)Men: 3.8% used sedative, hypnotic, anxiolytic; 1% used opioids\
Women: 6.8% used sedative, hypnotic, anxiolytic; 1.6% used opioidsMen: Risk drinkers (non-smoker) use of sedative, hypnotic or anxiolytic: 4.3% of 60--79 year olds\
Men: Risk drinkers (smokers) use of sedative, hypnotic or anxiolytic: 0% of 60--79 year olds\
Women: Risk drinker (non-smoker) use of sedative, hypnotic or anxiolytic: 13% of 60--79 year olds\
Women: Risk drinkers (smokers) use of sedative, hypnotic or anxiolytic: 0% of 60--79 year oldsLagnaoui 2001 \[[@CR36]\]56.3% drank wine (77.2% of men & 41.1% of women)\
Heavy drinking \>0.25 l wine/day: 15.3% (32.3% of men & 3.1% of women)32% used benzodiazepines15.7% reported concurrent use of alcohol (wine) and benzodiazepines & 2.9% reported concurrent heavy alcohol consumption (wine) and benzodiazepine useOverall benzodiazepine users: 49% consumed wine & 9.2% heavy drinkersOverall wine drinkers: 28.1% used benzodiazepines & heavy wine drinkers: 5.3% used benzodiazepinesSheahan 1995 \[[@CR32]\]38% drank alcohol in the past 12 months28% reported use of at least one psychotropic medication2% reported concurrent use of alcohol and psychotropic medicationVeldhuizen 2009 \[[@CR34]\]Not reportedNot reportedOverall benzodiazepine users: 33.9% consumed alcohol & 5.1% were heavy drinkers

Alcohol interactive (AI) medicines {#Sec11}
----------------------------------

Exposure to alcohol interactive medications varied across studies; nationally representative studies of community dwelling older adults using objective measures of AI exposure estimate exposure at between 72 and 79% among the total study samples (Table [3](#Tab3){ref-type="table"}) \[[@CR20], [@CR21]\]. Studies with objective measures of exposure to psychotropic medications in community dwelling older adults reported prevalence estimates of between 11.5--20% among the total study samples \[[@CR14], [@CR25], [@CR26]\]. In contrast to alcohol consumption, use of psychotropic medications was significantly higher in women than men \[[@CR14], [@CR22], [@CR25], [@CR28], [@CR32]\].

Concurrent use of alcohol and AI medications among older adults {#Sec12}
---------------------------------------------------------------

Eleven studies reported on the concurrent use of alcohol and alcohol interactive medications among the total study samples (Table [3](#Tab3){ref-type="table"}) \[[@CR14], [@CR18]--[@CR20], [@CR23], [@CR24], [@CR31]--[@CR33], [@CR35], [@CR36]\]. Eight of the 11 studies reported on alcohol consumption and a wide range of medicines with potential to interact with alcohol, with the prevalence of concurrent use ranging between 18 and 39% among the total study samples \[[@CR18]--[@CR20], [@CR23], [@CR24], [@CR31], [@CR33], [@CR35]\]. Only two of these studies were considered to have a low risk of misclassification bias for concurrent use \[[@CR20], [@CR31]\] . Breslow et al. estimated the prevalence of concurrent use among older adults at 35% \[[@CR20]\]. Concurrent use was highest for cardiovascular agents (28%) followed by metabolic agents (17%), CNS agents (10%) and coagulation modifiers (10%). Approximately 7.75% of all older adults were identified as concurrent users of alcohol and psychotropic medications \[[@CR20]\]. Qato et al. reported a prevalence estimate of 21%, with potential alcohol-medication interactions in older adults aged between 57 and 84 years being significantly more likely among men, white respondents, wealthier respondents, and those with higher education levels and greater comorbidities \[[@CR31]\]. The prevalence of concurrent use was lower in studies which focused on psychotropic medications, ranging between 2 and 15.7% \[[@CR14], [@CR32], [@CR36]\]. Only one study was identified as having a low risk of misclassifying concurrent use in older adults \[[@CR14]\], with an estimated prevalence of 7.4% among the total study sample and 2.4% for concurrent heavy alcohol consumption and psychotropic medications. Older age (70--79 years), residing in rural or small town areas, living alone, higher social status, polypharmacy and a poor social network were independently associated with concurrent use of alcohol and psychotropic medications \[[@CR14]\]. While a higher proportion (15.7%) of older adults in a French study \[[@CR36]\] were identified as concurrent users of wine and benzodiazepines, the methods of ascertaining exposure to benzodiazepines was unclear, as was the assessment of concurrent use. Similarly, the lower estimate of 2% for concurrent use of alcohol and psychotropic medications in Sheahan et al. \[[@CR32]\] is likely an artefact of their sample including patients in congregate care facilities.

Five studies assessed the prevalence of alcohol consumption among users of a broad range of alcohol interactive medications (Table [3](#Tab3){ref-type="table"}) \[[@CR19]--[@CR21], [@CR27], [@CR30]\]. Breslow \[[@CR20]\] and Cousins \[[@CR21]\] were identified as having a low risk of misclassifying concurrent use, and reported prevalence estimates of 45 and 60% respectively. Cousins et al. \[[@CR21]\] found that older adults using AI medications were significantly less likely to report alcohol consumption compared to those unexposed to AI medications. Younger age (60--64 years), men, urban dwelling, higher levels of education and a history of smoking were independently associated with concurrent use of alcohol and AI medications \[[@CR21]\]. A further six studies focused on psychotropic medication users \[[@CR14], [@CR22], [@CR25], [@CR26], [@CR34], [@CR36]\], four of which were identified as having a low risk of misclassification bias \[[@CR14], [@CR25], [@CR26], [@CR34]\]. Du et al. estimated the prevalence of alcohol consumption among users of psychotropic medications at 37.5% \[[@CR14]\]. Similarly, Ilomaki et al. \[[@CR25]\] reported that 38.9% of male psychotropic medication users, and 14.7% of their female users, consumed alcohol, with 26% of male and 8.3% of female users identified as heavy drinkers. Male psychotropic medication users consumed greater quantities of alcohol, and more often, than non-users. This pattern was not observed among women \[[@CR25]\]. Between one-third and a half of all sedative or hypnotic users (34--54%) have been shown to consume alcohol \[[@CR20], [@CR21], [@CR26], [@CR34]\] with between 5 and 13% drinking heavily \[[@CR21], [@CR34]\]. Consistent with these findings, Ilomaki et al. \[[@CR15]\] found that 26% of men aged greater than 70 years who use sedatives or hypnotics drink heavily; heavy drinking and daily drinking was significantly higher among male sedative or hypnotic users compared to non-users \[[@CR26]\]. Concurrent use of alcohol among older adults taking antidepressants ranged between 42 and 53%, \[[@CR20], [@CR21]\] with 27% of male users aged greater than 70 years reporting concurrent use \[[@CR26]\].

Adverse outcomes associated with concurrent use of alcohol and alcohol interactive medications {#Sec13}
----------------------------------------------------------------------------------------------

Only four studies reported on adverse outcomes. Three studies reported on falls, all three studies were cross-sectional \[[@CR27], [@CR32], [@CR35]\]. A study by Immonen et al. \[[@CR27]\] of 2100 older adults in Finland found that falls and injuries when a person has consumed alcohol in the past 12 months were more common among at risk drinkers (\>7 drinks/week, or ≥5 drinks drinking days or ≥3 drinks several times/week) using AI medications (13.8%) compared to AI medication-users who were not considered as at risk drinkers (4.1%) (*p* \< 0.001) \[[@CR27]\]. In contrast to these findings, Sheahan et al.'s \[[@CR32]\] study of older adults in America, which included patients in congregate care facilities, found that although the number of psychotropic drugs was associated with an increased odds of falling, the concurrent use of alcohol and psychotropic drugs was not. Similar non-significant associations were reported in Wong et al.'s \[[@CR35]\] convenience sample of older adults in the US. One study examined the association between moderate alcohol consumption (≤ 40 g of wine per day) and adverse drug reactions among older adults at the point of admission to one of 81 acute care hospitals in Italy \[[@CR29]\]. Among 22,778 participants, 3.9% were identified as having one or more adverse drug reactions. Moderate alcohol consumption was associated with a 24% increase in the odds of having an adverse drug reaction \[[@CR29]\].

Discussion {#Sec14}
==========

Overall, the results of this review suggest that between one-in-five and one-in-three older adults are potentially susceptible to alcohol-medication interactions, with more than half of AI medication users reporting alcohol consumption \[[@CR20], [@CR21], [@CR31]\]. However, these estimates need to be interpreted with caution as studies differed in their classification of AI medications. In the absence of an explicit list of alcohol-interactive medications, multiple drug reference sources were used across studies \[[@CR20], [@CR21], [@CR27], [@CR30], [@CR31]\]. Use of different medication compendia led to a lack of consistency in the inclusion of AI medications across studies and may have led to the over or under inclusion of medications \[[@CR31], [@CR37]\], resulting in an over-or-under estimate of concurrent use. There was however consensus with regards to CNS agents; all studies that reported on AI medicines classified CNS agents as alcohol interactive, specifically psychotropic medications \[[@CR14], [@CR18]--[@CR22], [@CR24]--[@CR32], [@CR34], [@CR36]\]. Based on the quality assessment of studies, the most reliable estimates for the concurrent use of psychotropic medications and alcohol ranged between 7.4% \[[@CR14]\] and 7.75% \[[@CR20]\].

Despite the high prevalence of concurrent use among older adults, no study examined longitudinal associations with adverse outcomes. Three cross-sectional studies reported on falls with mixed findings \[[@CR27], [@CR32], [@CR35]\]; with one study reporting on an association between moderate alcohol consumption and adverse drug reactions among older adults at the point of admission to hospital \[[@CR29]\]. An evidence based list of medications which have a significant risk of harm to older patients when combined with alcohol would be useful in a clinical setting, allowing for the identification of older adults whose alcohol consumption places them at increased risk and who would benefit from a preventative intervention. While recent studies have shown that clinicians rarely undertake screening and brief interventions to reduce alcohol consumption \[[@CR38]--[@CR40]\], flagging patients at the point of prescribing an alcohol-interactive medication may facilitate targeted screening and interventions to reduce harm. Brief alcohol interventions in primary care are effective in significantly reducing weekly alcohol consumption \[[@CR41]\]. Additionally, educating older adults in relation to the risks associated with concurrent use of alcohol and medications has been shown to increase older adults' awareness of potential risks \[[@CR42]\]. However, whether this intervention results in a behaviour change for those at risk is unclear \[[@CR42]\].

This is the first systematic review to examine the prevalence of concurrent use of alcohol and alcohol interactive medications and associated adverse outcomes in older adults. An explicit and robust methodology was applied to identify, critically appraise and synthesise the study findings. However, the findings of the review need to be interpreted in the context of the study limitations. The risk of misclassification bias for both alcohol and AI medications was high across many studies, undermining internal validity. Furthermore, no study directly measured the concurrent use of alcohol and AI medications, rather all studies inferred concurrent use. Finally, heterogeneity across studies in relation to classifying medications as alcohol interactive and in the methods used to quantify alcohol consumption, prevent statistical pooling of data from existing studies. Variation in study setting and age restrictions, also make it difficult to compare prevalence of concurrent use across studies. Furthermore, due to the current gap in the literature, the available evidence for this review was restricted to three continents, Europe, North America and Australia.

Conclusions {#Sec15}
===========

While there appears to be a high propensity for alcohol-medication interactions in community dwelling older adults, there is a lack of consensus regarding what constitutes an alcohol interactive medication. An explicit list of alcohol interactive medications needs to be derived, and validated prospectively to quantify the magnitude of risk posed by the concurrent use of alcohol and alcohol interactive medications for adverse outcomes in older adults. This will allow for risk stratification of older adults at the point of prescribing, and prioritise alcohol screening and brief alcohol interventions in high-risk groups.

Additional files
================

 {#Sec16}

Additional file 1:Database search: this document describes the retrieval process of studies for the systematic review. (DOCX 14 kb) Additional file 2:Search strategy: This file describes the search strategies used in Embase, PubMed, Web of Science and Scopus in order to identify studies for this systematic review. (DOCX 15 kb) Additional file 3:Newcastle-Ottawa Scale (NOS) adapted for cross-sectional studies. (DOC 35 kb) Additional file 4: Table S1.Most common alcohol interactive (AI) medicines across included studies. (DOCX 281 kb)

ADRs

:   Adverse drug reactions

AI

:   Alcohol interactive

AUD

:   Alcohol use disorder

NSAIDs

:   Nonsteroidal anti-inflammatory drugs

OTC

:   Over the counter
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